P-selectin is a nanotherapeutic delivery target in the tumor microenvironment

Science Translational Medicine

Volumn 8, Issue 345, 2016, Pages

  Shamay, Yosi ^a   Elkabets, Moshe ^a,b   Li, Hongyan ^a   Shah, Janki ^a   Brook, Samuel ^a   Wang, Feng ^a,c   Adler, Keren ^a,d   Baut, Emily ^a,e   Scaltriti, Maurizio ^a   Jena, Prakrit V ^a   Gardner, Eric E ^a,f   Poirier, John T ^a,e   Rudin, Charles M ^a,e   Baselga, José ^a   Haimovitz Friedman, Adriana ^a   Heller, Daniel A ^a,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

^d BRANDEIS UNIVERSITY   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; DOXORUBICIN; FUCOIDIN; NANOPARTICLE; PACLITAXEL; PADGEM PROTEIN; ANTINEOPLASTIC AGENT; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LIMIT OF QUANTITATION; LUNG METASTASIS; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE DRUG DOSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; COMPLICATION; DRUG EFFECTS; DRUG SCREENING; LUNG TUMOR; MELANOMA; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; RADIATION RESPONSE; SECONDARY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; P-SELECTIN; POLYSACCHARIDES; RADIATION, IONIZING; SPHEROIDS, CELLULAR; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978161586     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf7374     Document Type: Article

References (57)

1. E. K.-H. Chow, D. Ho, Cancer nanomedicine: From drug delivery to imaging. Sci. Transl. Med. 5, 216rv4 (2013).
2. M. Ferrari, Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
3. T. Lammers, F. Kiessling, W. E. Hennink, G. Storm, Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J. Control. Release 161, 175-187 (2012).
4. U. Prabhakar, H. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni, O. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski, D. C. Blakey, Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412-2417 (2013).
5. P. Grodzinski, D. Farrell, Future opportunities in cancer nanotechnology - NCI strategic workshop report. Cancer Res. 74, 1307-1310 (2014).
6. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
7. M. E. R. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAE-LYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440-449 (2004).
8. F. Curnis, A. Sacchi, A. Corti, Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110, 475-482 (2002).
9. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J. J. Song, Y. Ho Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P. W. Kantoff, N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, S. Zale, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012).
10. A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks, D. G. Anderson, Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12, 39-50 (2011).
11. G. S. Kansas, Selectins and their ligands: Current concepts and controversies. Blood 88, 3259-3287 (1996).
12. H. Läubli, L. Borsig, Selectins promote tumor metastasis. Semin. Cancer Biol. 20, 169-177 (2010).
13. L. Erpenbeck, M. P. Schön, Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427-3436 (2010).
14. H. Amano, Y. Ito, F. Ogawa, K. Eshima, T. Suzuki, K. Oba, Y. Matsui, S. Kato, T. Fukui, M. Nakamura, H. Kitasato, A. Fukamizu, M. Majima, Angiotensin II type 1A receptor signaling facilitates tumor metastasis formation through P-selectin-Mediated interaction of tumor cells with platelets and endothelial cells. Am. J. Pathol. 182, 553-564 (2013).
15. R. Bonfanti, B. C. Furie, B. Furie, D. D. Wagner, PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 73, 1109-1112 (1989).
16. D. E. Hallahan, S. Virudachalam, Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat. Res. 152, 6-13 (1999).
17. D. E. Hallahan, M. J. Staba-Hogan, S. Virudachalam, A. Kolchinsky, X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res. 58, 5216-5220 (1998).
18. C. D. Corso, A. N. Ali, R. Diaz, Radiation-induced tumor neoantigens: Imaging and therapeutic implications. Am. J. Cancer Res. 1, 390-412 (2011).
19. A. Z. Wang, J. E. Tepper, Nanotechnology in radiation oncology. J. Clin. Oncol. 32, 2879-2885 (2014).
20. L. Gong, H.-J. Mi, H. Zhu, X. Zhou, H. Yang, P-selectin-mediated platelet activation promotes adhesion of non-small cell lung carcinoma cells on vascular endothelial cells under flow. Mol. Med. Rep. 5, 935-942 (2012).
21. S. P. Gunningham, M. J. Currie, H. R. Morrin, E. Y. Tan, H. Turley, G. U. Dachs, A. I. Watson, C. Frampton, B. A. Robinson, S. B. Fox, The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. J. Pathol. 212, 335-344 (2007).
22. B. Hemmerlein, J. Scherbening, A. Kugler, H.-J. Radzun, Expression of VCAM-1, ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell carcinoma. Histopathology 37, 78-83 (2000).
23. G. Hariri, Y. Zhang, A. Fu, Z. Han, M. Brechbiel, M. N. Tantawy, T. E. Peterson, R. Mernaugh, D. Hallahan, Radiation-guided P-selectin antibody targeted to lung cancer. Ann. Biomed. Eng. 36, 821-830 (2008).
24. F. Rouzet, L. Bachelet-Violette, J.-M. Alsac, M. Suzuki, A. Meulemans, L. Louedec, A. Petiet, M. Jandrot-Perrus, F. Chaubet, J.-B. Michel, D. Le Guludec, D. Letourneur, Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation. J. Nucl. Med. 52, 1433-1440 (2011).
25. L. Bachelet, I. Bertholon, D. Lavigne, R. Vassy, M. Jandrot-Perrus, F. Chaubet, D. Letourneur, Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. Biochim. Biophys. Acta 1790, 141-146 (2009).
26. X. Li, W. Bauer, I. Israel, M. C. Kreissl, J. Weirather, D. Richter, E. Bauer, V. Herold, P. Jakob, A. Buck, S. Frantz, S. Samnick, Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: Correlation with in vivo 17.6T MRI. Arterioscler. Thromb. Vasc. Biol. 34, 1661-1667 (2014).
27. T. Bonnard, G. Yang, A. Petiet, V. Ollivier, O. Haddad, D. Arnaud, L. Louedec, L. Bachelet-Violette, S. M. Derkaoui, D. Letourneur, C. Chauvierre, C. Le Visage, Abdominal aortic aneurysms targeted by functionalized polysaccharide microparticles: A new tool for SPECT imaging. Theranostics 4, 592-603 (2014).
28. T. Bonnard, J.-M. Serfaty, C. Journé, B. Ho Tin Noe, D. Arnaud, L. Louedec, S. M. Derkaoui, D. Letourneur, C. Chauvierre, C. Le Visage, Leukocyte mimetic polysaccharide microparticles tracked in vivo on activated endothelium and in abdominal aortic aneurysm. Acta Biomater. 10, 3535-3545 (2014).
29. A. C. S. Carvalho, R. B. Sousa, Á. X. Franco, J. V. G. Costa, L. M. Neves, R. A. Ribeiro, R. Sutton, D. N. Criddle, P. M. G. Soares, M. H. L. P de Souza, Protective effects of fucoidan, a P- and L-selectin inhibitor, in murine acute pancreatitis. Pancreas 43, 82-87 (2014).
30. P. V. Jena, Y. Shamay, J. Shah, D. Roxbury, N. Paknejad, D. A. Heller, Photoluminescent carbon nanotubes interrogate the permeability of multicellular tumor spheroids. Carbon 97, 99-109 (2016).
31. J. Pan, L. Xia, L. Yao, R. P. McEver, Tumor necrosis factor-α- or lipopolysaccharide-induced expression of the murine P-selectin gene in endothelial cells involves novel κB sites and a variant activating transcription factor/cAMP response element. J. Biol. Chem. 273, 10068-10077 (1998).
32. A. Parodi, N. Quattrocchi, A. L. van de Ven, C. Chiappini, M. Evangelopoulos, J. O. Martinez, B. S. Brown, S. Z. Khaled, I. K. Yazdi, M. V. Enzo, L. Isenhart, M. Ferrari, E. Tasciotti, Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8, 61-68 (2013).
33. W. Yuan, G. Li, B. M. Fu, Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann. Biomed. Eng. 38, 1463-1472 (2010).
34. V. C. Daniel, L. Marchionni, J. S. Hierman, J. T. Rhodes, W. L. Devereux, C. M. Rudin, R. Yung, G. Parmigiani, M. Dorsch, C. D. Peacock, D. N. Watkins, A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69, 3364-3373 (2009).
35. S. Siva, M. P. MacManus, R. F. Martin, O. A. Martin, Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Lett. 356, 82-90 (2015).
36. G. Poste, J. Doll, I. J. Fidler, Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 78, 6226-6230 (1981).
37. A. J. Minn, G. P. Gupta, P. M. Siegel, P. D. Bos, W. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald, J. Massagué, Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
38. A. Fernández-Medarde, E. Santos, Ras in cancer and developmental diseases. Genes Cancer 2, 344-358 (2011).
39. D. Wang, S. A. Boerner, J. D. Winkler, P. M. LoRusso, Clinical experience of MEK inhibitors in cancer therapy. Biochim. Biophys. Acta 1773, 1248-1255 (2007).
40. C. Frémin, S. Meloche, From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 3, 8 2010).
41. P. A. Ascierto, D. Schadendorf, C. Berking, S. S. Agarwala, C. M. L. van Herpen, P. Queirolo, C. U. Blank, A. Hauschild, J. T. Beck, A. St-Pierre, F. Niazi, S. Wandel, M. Peters, A. Zubel, R. Dummer, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256 (2013).
42. V600E/K-mutated melanoma. Clin. Cancer Res. 19, 2257-2264 (2013).
43. C. Rosette, R. B. Roth, P. Oeth, A. Braun, S. Kammerer, J. Ekblom, M. F. Denissenko, Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26, 943-950 (2005).
44. Q. Chen, X. H.-F. Zhang, J. Massagué, Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538-549 (2011).
45. L. Righi, S. Deaglio, C. Pecchioni, A. Gregorini, A. L. Horenstein, G. Bussolati, A. Sapino, F. Malavasi, Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am. J. Pathol. 162, 1163-1174 (2003).
46. T. Iwamura, T. C. Caifrey, N. Kitamura, H. Yamanan, T. Setoguchi, M. A. Hoffingsworth, P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res. 57, 1206-1212 (1997).
47. A. N. Lukyanov, Z. Gao, L. Mazzola, V. P. Torchilin, Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm. Res. 19, 1424-1429 (2002).
48. P.-P. Lv, W. Wei, H. Yue, T.-Y. Yang, L.-Y. Wang, G.-H. Ma, Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration. Biomacromolecules 12, 4230-4239 (2011).
49. M. Verheij, R. Bose, X. Hua Lin, B. Yao, W. D. Jarvis, S. Grant, M. J. Birrer, E. Szabo, L. I. Zon, J. M. Kyriakis, A. Haimovitz-Friedman, Z. Fuks, R. N. Kolesnick, Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380, 75-79 (1996).
50. K. S. Mark, D. W. Miller, Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-α exposure. Life Sci. 64, 1941-1953 (1999).
51. V. V. Shuvaev, J. S. Brenner, V. R. Muzykantov, Targeted endothelial nanomedicine for common acute pathological conditions. J. Control. Release 219, 576-595 (2015).
52. P. Okunieff, D. Morgan, A. Niemierko, H. D. Suit Radiation dose-response of human tumors. Int. J. Radiat. Oncol. Biol. Phys. 32, 1227-1237 (1995).
53. J. Bernier, E. J. Hall, A. Giaccia, Radiation oncology: A century of achievements. Nat. Rev. Cancer 4, 737-747 (2004).
54. K. M. Prise, New advances in radiation biology. Occup. Med. 56, 156-161 (2006).
55. A. Prasanna, M. M. Ahmed, M. Mohiuddin, C. Norman Coleman, Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. J. Thorac. Dis. 6, 287-302 (2014).
56. E. C. Dreaden, Y. Wen Kong, S. W. Morton, S. Correa, K. Young Choi, K. E. Shopsowitz, K. Renggli, R. Drapkin, M. B. Yaffe, P. T. Hammond, Tumor-targeted synergistic blockade of MAPK and PI3K from a layer-by-layer nanoparticle. Clin. Cancer Res. 21, 4410-4419 (2015).
57. E. K.-H. Chow, L.-l. Fan, X. Chen, J. M. Bishop, Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology 56, 1331-1341 (2012).